
Patents
Towards the start of the trilogue on GMO deregulation?
On 14 March 2025, the Member States of the European Union achieved a fragile qualified majority to launch a discussion with the European Commission and the European Parliament on the deregulation of GMOs. It took the member states almost two years to reach this majority, as there are still many disagreements. Negotiations between the three European decision-making bodies – known as a “trilogue” – could now get underway, subject to the vote of a final formal mandate by the European Parliament’s Environment Committee.

Ethic
The European Patent Office outlines a fragile ethical frontier
In September 2024, the European Patent Office (EPO) refused a patent for human-pig chimeras on the basis of the ethical rules governing patentability in biotechnology. By invoking the protection of “human dignity”, the EPO is drawing a sometimes fluctuating line between innovation and respect for fundamental values. This decision sets a – perhaps fragile – precedent for inventions affecting human identity, and highlights the complexity of an ethical framework in the era of unbridled biotechnology.

Patents
The European Commission’s proposal to deregulate GMOs does cover some GMO micro-organisms
In July 2023, the European Commission’s proposal to deregulate GMOs was presented and understood as concerning only plants. Micro-organisms, animals and fungi would not be concerned. However, a careful reading will show that, contrary to what the European Parliament seems to have understood, some micro-organisms are indeed concerned… because they are considered to be plants!

Health
Authorization
Self-amplifying messenger RNA “vaccine”: after the human, the duck
A year and a half ago, France made it compulsory to vaccinate farmed ducks against the avian influenza virus, in order to protect its meat and foie gras industries. To date, France is the only country to have taken this vaccination route. One of the two vaccines used, the self-amplifying messenger RNA (mRNA) vaccine, raises questions.

GMO perception
In 2025, more and more organisations are opposed to the deregulation of GMOs
In February 2025, two statements opposing the European Commission’s proposal to deregulate GMOs were published. On 11 February 2025, more than 200 organisations, including farming unions, NGOs, small and medium-sized breeders, and players in the organic and non-GMO sectors, published a “joint declaration on the deregulation of new GMOs”. On 21 February 2025, more than 70 French players in the organic sector published a collective opinion piece online in Mediapart.

Biopiracy
Despite negotiations in 2024, disagreements over DSI persist
In 2024, digital sequence information (DSI) derived from genetic resources was at the heart of international negotiations. Discussions focused mainly on the sharing of the benefits generated by the industrial and commercial use of this DSI, and the mechanisms required to implement it. These developments could redefine governance and influence the future regulation of DSI, but persistent differences between countries are holding back progress.

Health
Transgenesis
Male mosquitoes genetically modified to produce poison
Mosquitoes carry pathogens that cause diseases such as malaria and dengue fever, and are therefore known as vector-borne diseases. As part of the fight against these mosquitoes, researchers at Macquarie University (Australia) are considering a new genetic strategy. The idea is to genetically modify male mosquitoes so that their sperm produce molecules that will poison female mosquitoes.

Research governance
Nanotechnologies in the field: nothing new in twenty years?
Patents involving the use of nanos* in agriculture have multiplied over the last 20 years. However, there has been no improvement in the availability of information in this field. A recent report, commissioned by AVICENN and published by the European Chemicals Agency (ECHA), re-emphasizes the need to change European regulations in order to better identify, assess and manage nanos in the fields and the food. AVICENN is calling for greater transparency on the marketing and risks of nanomaterials that have long been used in agriculture.

Mutagenesis
Patents and GMOs: different stakeholders, different solutions
Since July 2023, the issue of patents on living organisms has been at the heart of debates in the European Union. These debates were sparked by the European Commission’s proposal to stop assessing the risks associated with GMOs, to stop labelling them as such, and to put an end to their detection and identification. In December 2024, a conference allowed several stakeholders of the debate to express their opinion.